secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2026-01-28T23:59:59+00:00
Accession:  0001193125-26-027203
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Tempest shareholders approve share issuance for asset purchase and extend rights plan
--------------------------------------------------------------------------------

- Approved issuance of 8,268,495 common shares for Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc.
- Stockholders extended limited duration rights plan to October 10, 2026.
- Amendment to 2023 Equity Incentive Plan approved, increasing share reserve by 1,410,000 shares.
- Geoff Nichol elected Class I director with 1,003,845 votes for; broker non-votes 1,075,928.
- Advisory say-on-pay approved with 816,856 votes for, 428,524 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526027203/0001193125-26-027203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526027203/d70064d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-027203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer